| James Patrick Savage, OD | |
|
43 Hatch Dr, Suite 150, Caribou, ME 04736-2161 | |
| (207) 498-2538 | |
| (207) 498-2539 |
| Full Name | James Patrick Savage |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 40 Years |
| Location | 43 Hatch Dr, Caribou, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609934751 | NPI | - | NPPES |
| 410005857 | Other | ME | RAILROAD MEDICARE |
| 006663 | Other | ME | ANTHEM |
| 247110099 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OPT714 (Maine) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maine Optometry Pa | 8022009117 | 19 |
News Archive
A team of researchers at the Norwegian University of Science and Technology (NTNU) investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.
Pfizer Inc. and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.
"Miami likes glitz",explains Christopher Craft, M.D., which is why women here tend to get larger breast implants in comparison to the rest of the country. Craft attended Georgetown University, graduated from the University of Tennessee Medical School, and completed his plastic surgery training at the University of North Carolina at Chapel Hill. He's a trained general and plastic surgeon specializing in surgical procedures of the body, breasts and skin.
› Verified 6 days ago
| Provider Name | Maine Optometry Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1437182383 PECOS PAC ID: 8022009117 Enrollment ID: O20040519000050 |
News Archive
A team of researchers at the Norwegian University of Science and Technology (NTNU) investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.
Pfizer Inc. and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.
"Miami likes glitz",explains Christopher Craft, M.D., which is why women here tend to get larger breast implants in comparison to the rest of the country. Craft attended Georgetown University, graduated from the University of Tennessee Medical School, and completed his plastic surgery training at the University of North Carolina at Chapel Hill. He's a trained general and plastic surgeon specializing in surgical procedures of the body, breasts and skin.
› Verified 6 days ago
| Provider Name | Caribou Eyecare, P.a. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1356470645 PECOS PAC ID: 4284642539 Enrollment ID: O20060328000310 |
News Archive
A team of researchers at the Norwegian University of Science and Technology (NTNU) investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.
Pfizer Inc. and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.
"Miami likes glitz",explains Christopher Craft, M.D., which is why women here tend to get larger breast implants in comparison to the rest of the country. Craft attended Georgetown University, graduated from the University of Tennessee Medical School, and completed his plastic surgery training at the University of North Carolina at Chapel Hill. He's a trained general and plastic surgeon specializing in surgical procedures of the body, breasts and skin.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Patrick Savage, OD Po Box 280, Caribou, ME 04736-0280 Ph: (207) 498-2538 | James Patrick Savage, OD 43 Hatch Dr, Suite 150, Caribou, ME 04736-2161 Ph: (207) 498-2538 |
News Archive
A team of researchers at the Norwegian University of Science and Technology (NTNU) investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.
Pfizer Inc. and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, today announced the initiation of a Phase 1 clinical study of ACE-041, a novel angiogenesis inhibitor that binds to and prevents members of the TGF-β superfamily from signaling through the activin receptor-like kinase 1 (ALK1) receptor.
"Miami likes glitz",explains Christopher Craft, M.D., which is why women here tend to get larger breast implants in comparison to the rest of the country. Craft attended Georgetown University, graduated from the University of Tennessee Medical School, and completed his plastic surgery training at the University of North Carolina at Chapel Hill. He's a trained general and plastic surgeon specializing in surgical procedures of the body, breasts and skin.
› Verified 6 days ago
Dr. Rachel Marie Bradford, OD, MPH Optometrist Medicare: Not Enrolled in Medicare Practice Location: 43 Hatch Dr, Caribou, ME 04736 Phone: 207-498-2538 | |
Abby Small, OD Optometrist Medicare: Medicare Enrolled Practice Location: 37 Herschel St, Caribou, ME 04736 Phone: 207-496-5111 | |
Dr. Craig K Small, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 37 Herschel St, Caribou, ME 04736 Phone: 207-496-5111 Fax: 207-498-6502 | |
Paige Small, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 37 Herschel St, Caribou, ME 04736 Phone: 207-496-5111 | |
Caribou Eyecare, P.a. Optometrist Medicare: Medicare Enrolled Practice Location: 43 Hatch Dr, Suite 150, Caribou, ME 04736 Phone: 207-498-2538 Fax: 207-498-2539 | |
Daniel Joseph Jandreau, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 43 Hatch Dr, Suite 150, Caribou, ME 04736 Phone: 207-498-2538 Fax: 207-498-2539 |